LON:STX - Shield Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started GBX 63 0.00 (0.00 %) (As of 03/20/2019 01:23 PM ET)Previous CloseGBX 63Today's RangeGBX 62 - GBX 6352-Week RangeGBX 14 - GBX 73Volume10,158 shsAverage Volume48,665 shsMarket Capitalization£73.35 millionP/E Ratio-4.06Dividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartInsider TradesHeadlinesOptions Chain Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Shield Therapeutics plc, a specialty pharmaceutical company, in the development and commercialization of hospital-focused pharmaceuticals to treat unmet medical needs. Its lead product is Feraccru, a novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease. Its advanced pipeline asset is PT20, a novel therapy that has completed its Phase IIb pivotal clinical trial for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also develops PT30 and PT40 intravenous iron formulations. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom. Receive STX News and Ratings via Email Sign-up to receive the latest news and ratings for STX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange LON Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolLON:STX Previous Symbol CUSIPN/A CIKN/A Webwww.shieldtherapeutics.com Phone+44-191-5118500Debt Debt-to-Equity RatioN/A Current Ratio1.69 Quick Ratio1.64Price-To-Earnings Trailing P/E Ratio-4.06 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales£990,000.00 Price / Sales74.09 Cash FlowGBX 2.84 per share Price / Cash Flow22.17 Book ValueGBX 28.80 per share Price / Book2.19Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees20 Outstanding Shares116,426,000Market Cap£73.35 million Next Earnings DateN/A OptionableOptionable Shield Therapeutics (LON:STX) Frequently Asked Questions What is Shield Therapeutics' stock symbol? Shield Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "STX." What price target have analysts set for STX? 2 Wall Street analysts have issued 12-month target prices for Shield Therapeutics' shares. Their forecasts range from GBX 88 to GBX 116. On average, they anticipate Shield Therapeutics' share price to reach GBX 102 in the next twelve months. This suggests a possible upside of 61.9% from the stock's current price. View Analyst Price Targets for Shield Therapeutics. What is the consensus analysts' recommendation for Shield Therapeutics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Shield Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Shield Therapeutics. Has Shield Therapeutics been receiving favorable news coverage? Press coverage about STX stock has been trending somewhat positive on Wednesday, according to InfoTrie Sentiment. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Shield Therapeutics earned a daily sentiment score of 1.7 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. Who are some of Shield Therapeutics' key competitors? Some companies that are related to Shield Therapeutics include Depomed (ASRT), Benchmark (BMK), ICC Labs (ICC), WeedMD (WMD), Delta 9 Cannabis (NINE), Biosyent (RX), Zomedica Pharmaceuticals (ZOM), Auscann Group (AC8), Probiotec (PBP), Invion (IVX), Science in Sport (SIS), MMJ Group (MMJ), Cipher Pharmaceuticals (CPH), Viridium Pacific Group (VIR) and Indiva (NDVA). What other stocks do shareholders of Shield Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Shield Therapeutics investors own include United States Brent Oil Fund (BNO), National Bank of Canada (NA), Velocity Data (VCT), AAR (AIR), Lendlease Group (LLC), Constellation Brands (STZ), Mid-America Apartment Communities (MAA), iShares Transportation Average ETF (IYT), Riot Blockchain (RIOT) and ABM Industries (ABM). Who are Shield Therapeutics' key executives? Shield Therapeutics' management team includes the folowing people: Mr. Carl Sterritt, Co-Founder, CEO & Director (Age 51)Mr. Timothy William Watts, Chief Financial Officer (Age 61)Fleur Wood, Director of Investor RelationsMs. Lucy Bailey, Gen. Counsel & Company Sec.Ms. Suzanne Wood, Group HR Director How do I buy shares of Shield Therapeutics? Shares of STX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Shield Therapeutics' stock price today? One share of STX stock can currently be purchased for approximately GBX 63. How big of a company is Shield Therapeutics? Shield Therapeutics has a market capitalization of £73.35 million and generates £990,000.00 in revenue each year. Shield Therapeutics employs 20 workers across the globe. What is Shield Therapeutics' official website? The official website for Shield Therapeutics is http://www.shieldtherapeutics.com/. How can I contact Shield Therapeutics? Shield Therapeutics' mailing address is 3rd Fl Baltic Business Quarters, Abbott's Hill, GATESHEAD, NE8 3D, United Kingdom. The company can be reached via phone at +44-191-5118500. MarketBeat Community Rating for Shield Therapeutics (LON STX)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 160 (Vote Outperform)Underperform Votes: 115 (Vote Underperform)Total Votes: 275MarketBeat's community ratings are surveys of what our community members think about Shield Therapeutics and other stocks. Vote "Outperform" if you believe STX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/20/2019 by MarketBeat.com StaffFeatured Article: How do taxes affect a CDs total return?